Oramed Pharmaceuticals Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Nadav Kidron
Chief executive officer
US$1.7m
Total compensation
CEO salary percentage | 27.9% |
CEO tenure | 18yrs |
CEO ownership | 2.9% |
Management average tenure | 11.3yrs |
Board average tenure | 7.5yrs |
Recent management updates
Recent updates
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Aug 24Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
May 03Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Dec 22Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality
Sep 21Oramed to hand Korean rights for insulin capsule
Sep 09Oramed to report early-stage trial data for oral COVID-19 shot in 3Q
Jul 07Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?
Jun 12Oramed And Oral Insulin: Can This Small Company Really Do It?
Apr 14Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Feb 23Oramed And The Hurdles Of Developing Oral Insulin
Dec 23Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Nov 02Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress
Oct 04We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation
Aug 24Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
Jul 21Oramed reaches 50% enrollment in late-stage oral insulin study
Jun 08Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
Apr 06The Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Is Up 110% And Shareholders Are Boasting About It
Feb 12Oramed Pharmaceuticals EPS beats by $0.42, revenue in-line
Jan 14Why Oramed Pharmaceuticals' (NASDAQ:ORMP) CEO Pay Matters
Jan 08Oramed's obesity drug candidate shows decrease in glucose levels
Dec 23We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Can Afford To Drive Business Growth
Dec 04Oramed launches late-stage NASH study with oral insulin
Dec 02CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | US$2m | US$463k | US$6m |
Sep 30 2023 | n/a | n/a | -US$16m |
Jun 30 2023 | n/a | n/a | -US$20m |
Mar 31 2023 | n/a | n/a | -US$30m |
Dec 31 2022 | US$7m | US$491k | -US$37m |
Sep 30 2022 | n/a | n/a | -US$46m |
Jun 30 2022 | n/a | n/a | -US$46m |
Mar 31 2022 | n/a | n/a | -US$40m |
Dec 31 2021 | n/a | n/a | -US$35m |
Nov 30 2021 | n/a | n/a | -US$25m |
Aug 31 2021 | US$4m | US$466k | -US$22m |
May 31 2021 | n/a | n/a | -US$18m |
Feb 28 2021 | n/a | n/a | -US$15m |
Dec 31 2020 | n/a | n/a | -US$22m |
Nov 30 2020 | n/a | n/a | -US$15m |
Aug 31 2020 | US$2m | US$439k | -US$12m |
May 31 2020 | n/a | n/a | -US$11m |
Feb 29 2020 | n/a | n/a | -US$13m |
Nov 30 2019 | n/a | n/a | -US$13m |
Aug 31 2019 | US$2m | US$419k | -US$14m |
May 31 2019 | n/a | n/a | -US$15m |
Feb 28 2019 | n/a | n/a | -US$15m |
Nov 30 2018 | n/a | n/a | -US$14m |
Aug 31 2018 | US$2m | US$436k | -US$13m |
May 31 2018 | n/a | n/a | -US$12m |
Feb 28 2018 | n/a | n/a | -US$10m |
Nov 30 2017 | n/a | n/a | -US$10m |
Aug 31 2017 | US$1m | US$400k | -US$10m |
Compensation vs Market: Nadav's total compensation ($USD1.66M) is above average for companies of similar size in the US market ($USD661.05K).
Compensation vs Earnings: Nadav's compensation has been consistent with company performance over the past year.
CEO
Nadav Kidron (49 yo)
18yrs
Tenure
US$1,659,222
Compensation
Mr. Nadav Kidron, Esq. has been the Chief Executive Officer and President of Oramed Pharmaceuticals Inc. (Alternatively Integrated Security Technologies Inc) since March 08, 2006. Mr. Kidron served as an i...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 18yrs | US$1.66m | 2.88% $ 3.4m | |
CFO & Treasurer | 2.7yrs | US$536.71k | 0.22% $ 264.5k | |
Chief Scientific Officer & Director | 18yrs | US$1.11m | 0.21% $ 250.7k | |
Chief Operating & Business Officer | 4.5yrs | US$1.28m | 0.43% $ 502.9k |
11.3yrs
Average Tenure
51yo
Average Age
Experienced Management: ORMP's management team is seasoned and experienced (11.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 18yrs | US$1.66m | 2.88% $ 3.4m | |
Chief Scientific Officer & Director | 18yrs | US$1.11m | 0.21% $ 250.7k | |
Member of Scientific Advisory Board | 4.2yrs | no data | no data | |
Member of Scientific Advisory Board | 17.1yrs | no data | no data | |
Member of Scientific Advisory Board | 7.3yrs | US$20.00k | no data | |
Member of Scientific Advisory Board | 15.7yrs | no data | no data | |
Member of Scientific Advisory Board | 4.3yrs | no data | no data | |
Independent Director | 16.4yrs | US$112.28k | 0.068% $ 80.6k | |
Member of the Scientific Advisory Board | 7.7yrs | no data | no data | |
Member of Scientific Advisory Board | 1.8yrs | no data | no data | |
Independent Director | 4.3yrs | US$127.28k | 0.064% $ 75.1k | |
Member of Scientific Advisory Board | 4.2yrs | no data | no data |
7.5yrs
Average Tenure
69yo
Average Age
Experienced Board: ORMP's board of directors are considered experienced (7.5 years average tenure).